BFRIHealthcare · Drug Manufacturers - Specialty & GenericThe 2 Wall Street analysts covering Biofrontera, Inc. hold a median 12-month price target of $6 — +311.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 66 of 100 as at 22 Aug 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores Biofrontera, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (92): Sales and profits are climbing, and climbing faster than before.
Issuance (7): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on BFRI, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +311.0% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 19 May 2026 | Benchmark | Downgrade | Speculative Buy | $3.00 |
| 19 May 2025 | Benchmark | Maintains | Buy | — |
| 15 Nov 2024 | Benchmark | Reiterates | Buy | — |
| 16 Aug 2024 | Benchmark | Reiterates | Buy | — |
| 31 Aug 2023 | Benchmark | Reiterates | Buy | — |
| 5 July 2023 | Benchmark | Maintains | Buy | $140 → $18 |
| 15 May 2023 | Benchmark | Reiterates | Buy | $7.00 |
| 9 Mar 2023 | Benchmark | Reiterates | Buy | $7.00 |
| 31 Jan 2023 | Benchmark | Reiterates | Buy | $11 → $7.00 |
| 15 Dec 2021 | Benchmark | Initiates | Buy | $11 |
| 24 Nov 2021 | Roth Capital | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. BFRI appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 24 Aug 2026, Biofrontera, Inc. returned +51.5% against +19.6% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 71% of US stocks
Cheaper than 84% of US stocks
Cheaper than 30% of US stocks
Cheaper than 77% of US stocks
Higher than 80% of US stocks
Higher than 90% of US stocks
Higher than 28% of US stocks
Higher than 18% of US stocks
Higher than 1% of US stocks
Higher than 21% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Biofrontera, Inc. has a market value of $22.0M and an enterprise value of $24.8M.
Revenue in the twelve months to 31 Mar 2026: $43.2M. The latest quarter grew 32.9% year on year.
Net income over the same four quarters: −$11.1M, a −25.7% net margin.
Diluted earnings per share, trailing twelve months: $−1.12.
Free cash flow in the twelve months to 31 Mar 2026: −$9.3M, after $4K of capital spending.
Trailing P/E: 0.9×; forward P/E: 3.5× — the forward figure prices analyst consensus estimates, not reported earnings.
Biofrontera, Inc. employs 84 people — $514K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Biofrontera, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Seeking Alpha published the transcript of Biofrontera Inc.'s Q2 2026 earnings call. The item indicates the earnings call transcript is now available but provides no specific financial details or commentary.
Why it matters — A BFRI watcher would care because the earnings call transcript is the primary source for management's discussion of the company's second-quarter performance and outlook.
Biofrontera Inc. reported a second-quarter loss of $0.05 per share, which was narrower than the Zacks Consensus Estimate of a $0.17 loss and an improvement from the $0.57 per share loss reported a year ago. The company beat revenue estimates for the quarter.
Why it matters — The narrower-than-expected loss and revenue beat signal improving financial performance relative to analyst expectations, which BFRI watchers would find relevant.
Biofrontera Inc. reported its financial results for the second quarter ended June 30, 2026, highlighting 33% revenue growth as a key driver of strong performance.
Why it matters — The 33% revenue growth signals accelerating commercial traction for Biofrontera's dermatology PDT business, a key metric for investors tracking the company's financial trajectory.
Biofrontera Inc. (NASDAQ: BFRI) announced it will report its financial results for the second quarter ended June 30, 2026, before the market opens on Thursday, August 13, 2026. The announcement was made via GlobeNewsWire on August 5, 2026.
Why it matters — BFRI watchers can expect the company's second-quarter 2026 results to be released on August 13, which sets the timeline for its next financial disclosure.
The 2 Wall Street analysts covering Biofrontera, Inc. have a median 12-month price target of $6, with estimates ranging from $3 to $9. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 2 analysts covering Biofrontera, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Biofrontera, Inc. 66 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 22 Aug 2026, Biofrontera, Inc. ranks 66 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (92 of 100).
No one can know that. What the data says: the median 12-month target from 2 analysts implies +311.0% from the last close, and Ticker Nerd's factor model ranks Biofrontera, Inc. 66 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Biofrontera, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BFRI are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $3 to $9 over the next 12 months.
Biofrontera, Inc. returned +51.5% over the 12 months to 24 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Biofrontera Inc. is a specialty pharmaceutical company focused on the development and commercialization of dermatological products.
The most recent item we track (Seeking Alpha, 13 Aug 2026): "Biofrontera Inc. (BFRI) Q2 2026 Earnings Call Transcript". Seeking Alpha published the transcript of Biofrontera Inc.'s Q2 2026 earnings call. The item indicates the earnings call transcript is now available but provides no specific financial details or commentary.
Biofrontera Inc. is a specialty pharmaceutical company focused on the development and commercialization of dermatological products. Its primary aim is to address unmet needs in the treatment of skin diseases, with a particular emphasis on dermatology, represented by its flagship product, Ameluz. This prescription medication is used in photodynamic therapy to treat actinic keratosis and basal cell carcinoma, offering a non-invasive option for patients. Biofrontera Inc. also owns a range of other topical dermatology treatments and has made strategic partnerships to enhance its market presence. By driving innovation in skin health solutions, the company impacts the healthcare industry, notably benefiting dermatologists and their patients. Based in Woburn, Massachusetts, Biofrontera plays a significant role in dermatological therapeutics, striving to expand its product portfolio through continuous research and development. Its dedication to providing effective solutions for skin conditions aligns with broader trends in personalized and targeted healthcare, making it a notable player in the specialty pharma space.
CEO Dr. Hermann Luebbert Ph.D. · 84 employees · United States · https://www.biofrontera-us.com
